



**CHRISTOPHER P. MOLINEAUX**

PRESIDENT & CEO  
LIFE SCIENCES PENNSYLVANIA

## IN THIS ISSUE

President's Message..... 1

Advocacy ..... 3

Pittsburgh BioBreakfast's Fall  
Flu Vaccination Clinic..... 7

Events ..... 9

Membership ..... 14

2020 New Members .....17

LSPA Team..... 18

## DEAR MEMBERS OF LIFE SCIENCES PA:

Many of our member companies have told me they are still grappling with how to approach the topic of diversity and inclusion. Out of deference to the topic, I am dedicating the space in this issue we ordinarily devote to my President's Column to hear directly from Black leaders in the life sciences community about how things have changed since the events of early this summer. Special thanks to Life Sciences PA Board member, Bert Bruce of Pfizer for coordinating the responses below and to his colleagues in [Get Together Group](#) for sharing their thoughts. Get Together Group is a biopharmaceutical non-profit organization with specific focus on leadership development, career planning, and mentoring for African Americans and other ethnically diverse individuals.

### THOMAS G. KOLARAS, SENIOR VICE PRESIDENT OF MARKETING, BRANDED PHARMACEUTICALS, ENDO PHARMACEUTICALS

#### How has the environment changed in your organization since George Floyd's murder at the end of May?

*This is challenging to answer with one thought, because today's environment is somewhat artificial because of COVID. With that said, I will use the word climate if you approve. It has changed with the right intentions. Higher sensitivity to equality for all people; formation of DE&I initiatives; and a newly established position with an experienced and talented lead for DE&I. Now that the most startling events have somewhat subsided, it will be interesting to see how much energy and willingness people have to remain focused on the mission.*

#### How has your company engaged with you since that time?

*I was asked and proudly accepted being a founding member on our DE&I council. We have a solid platform to begin building. We hired a new head of DE&I. And we have our CEO as chair with other distinct C-level executives as active members. Overall, the company is working towards a place where all people feel respected and heard in this ever-changing world.*

#### What advice would you give to individuals who want to understand an experience different from their own? In other words, what advice do you give someone who doesn't want to do the "wrong" thing, but isn't sure what the "right" thing is?

*We all come to the table with distinct and important positions on life, work, family, relationships, spirituality and the like. This may sound unauthentic, but please, "Be you." I want to meet the person...not their representative. Forge forward into your beliefs and they will guide you in the right direction. When we hold back on our own truth, we lie to the most important person—ourselves.*

### What are tangible ways the life sciences industry can address systemic racism?

*Yes...my favorite question! We first need to acknowledge that this insidious undercurrent has and will continue to exist. Let's not stick our heads in the sand. Someone that is respected, not black or a person of color, has to be courageous and say that this is real and it must stop today. Show the change that you desire, by putting qualified black people in positions that really matter to the business—I promise they will not let you down. We can only pretend so long. When C-suites, Board rooms and other highly sought after positions of power and influence are under 1% representation of black people. I don't think we need a statistician to figure out what's wrong.*

*So what do we do.*

*Engage Everyone—let people talk, vent, cry, think, absorb and release. The life sciences industry should facilitate these discussions, just the same way as we gather for hot topics in clinical development. If it matters, then make it important!*

*Take active steps that show sincerity. Formation of councils with experienced leaders; charters that have real human relatability--what is written has to resonate to the masses.*

*Hire the people you don't see today. There are a plethora of multi-talented, hard-working and over-qualified people of color, specifically, black people that are ready to change, engage and deliver exceptional results for their company. Formation of mentorship programs; the Black MBA or Engineers societies; social mixers and incubation meetings. A little effort will make us all better people.*

*Stop talking. Start doing.*

**GARY D. BRANCH, VICE PRESIDENT, SALES,  
LEO PHARMA INC.**

### How has the environment changed in your organization since George Floyd's murder at the end of May?

*We're a small Danish medical dermatology company. We now have a DE&I team made of individuals across the organization with Executive Leadership sponsorship. This team is setting the direction of where they will take the organization. Following the murder of George Floyd, there was a statement by the US President.*

### How has your company engaged with you since that time?

*The company has reached out to me for insights, thoughts, and feedback. Having been in the industry for close to 30 years and have seen many highs and lows, I am adamant that the majority drive these types of initiatives. This way they won't be seen as people of color on their "soap boxes". I have mentored those individuals.*


### What advice would you give to individuals who want to understand an experience different from their own? In other words, what advice do you give someone who doesn't want to do the "wrong" thing, but isn't sure what the "right" thing is?

*You need to get out of your comfort zone. The thoughts of many are based solely on what they may see or read. If you truly want to understand someone else's experience, walk in their shoes. Immerse yourself in their environment. Don't just invite them into your environment. Don't worry about doing the "wrong" thing. If you have concerns, ask questions or have a dialogue. If you do say something inappropriate and you're corrected, seek to understand why it was inappropriate or why someone may be offended.*

### What are tangible ways the life sciences industry can address systemic racism?

*I always say that if a company's board and executive leadership are not a sampling of what you want the organization to be, then they are just blowing smoke. For this to be, a company must look at how they staff, recruit, train, develop, promote, and how opportunities are provided. Furthermore, they must understand the business implication of having diverse teams. People of color are not monolithic.*

Sincerely,



Christopher P. Molineaux

## VIRTUAL LSPA COMMUNITY ... WHILE WE'RE ALL WORKING REMOTELY



**SEND  
MESSAGES**



**EXCHANGE  
CONTACT INFO**



**SHARE  
UPDATES**

**CLICK HERE TO JOIN**

# ADVOCACY

## FEDERAL



### FEDERAL BUDGET AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER

President Trump signed a Continuing Resolution (CR) October 1 that ensures the government remains funded through December 11, 2020. Had a deal not been reached, the federal government would have shut down after 11:59 p.m. September 30. Importantly, this legislation does not include any policy riders that mirror any of the President's recently signed executive orders.


Also important to the Life Sciences PA membership is the short-term extension of the Rare Pediatric Disease Priority Review Voucher (PRV) program included in this funding package. While it is not the long-term program reauthorization Life Sciences PA would prefer, it does ensure the program will continue past its September 30 sunset date. According to the legislation, the program is extended through the life of the CR, which concludes December 11, 2020. As it stands, after that date and until December 11, 2022, products may only receive vouchers if they received the rare pediatric designation prior to December 11, 2020.

Life Sciences PA will continue to work with Senator Casey, the Senate Democrat lead on this reauthorization, on a long-term extension to this program, which is critical to incentivizing the research and development of novel medicines for children with rare disorders.



### MULTI-STATE CONGRESSIONAL BRIEFING

Life Sciences PA was pleased to work with our state association partners – Biocom, BioNJ, CLSA, HINJ, and MichBio – to host a multi-state congressional briefing July 7. The discussion focused on *Research and Development Amid a Pandemic* and panelists provided the more than 80 congressional staff that registered with information on how life sciences entities continue to forge ahead in the discovery of novel medicines and technologies amid a global pandemic. Speakers at the event included Dr. Kelsey Martin, Dean, David Geffen School of Medicine, UCLA; Dr. Jeff Castelli, Chief Development Officer, Amicus Therapeutics; Dr. Michael Dudley, President and CEO at QPEX Biopharma; Dr. David Fajgenbaum, Co-Founder and Executive Director, Castleman Disease Collaborative Network.



Dr. David Fajgenbaum provides an overview of how rare disease patients have been affected by the COVID-19 pandemic.



### COVID-19 PACKAGE STALLED

Congress authorized approximately \$3 trillion in four COVID-19 relief packages passed between March 4 and April 24. However, discussions about another relief package stalled as House and Senate leadership and the White House failed to come to an agreement before Congress adjourned for its August district work period. Very little progress, if any at all, has been made since Congress returned to session in September.

Despite the delay and uncertain future of another relief package, Life Sciences PA continues to advocate for policies that incentivize innovation amid a pandemic:

- **DISARM Act:** a bill to incentivize the development of novel antimicrobial resistant medicines
- **NIH Funding/Research Relief:** robust and supplemental funding to ensure COVID-19 basic research and research for other unmet medical needs can continue at the Commonwealth's academic research institutions
- **Rare Pediatric Priority Review Voucher:** reauthorizing a long-term extension of the Priority Review Voucher for companies researching medicines for rare pediatric disorders

Along with those specific proposals, Life Sciences PA continues to have conversations with the Pennsylvania congressional delegation around funding and policies – such as additions to the Paycheck Protection Plan, possibly reauthorizing the Quality Therapeutic Discovery Project (QTD), and the IGNITE American Innovation Act (HR 7917) – all of which would be beneficial to small and growing Member companies facing investment and liquidity issues.





## SAFE TO WORK ACT

As part of a coalition of statewide associations, Life Sciences PA signed on to a letter urging Senator Toomey to co-sponsor the SAFE TO WORK Act (S. 4317). This bill, introduced by Senator Cornyn (R-TX), provides reasonable, temporary, and limited liability protection to businesses, schools, and other entities that make reasonable efforts to follow public health guidelines. This protection would allow those who are already taking precautions promoting safety to focus their resources on their recovery rather than on the extensive litigation costs that can accompany frivolous lawsuits. Importantly, the SAFE TO WORK Act does not protect bad actors who engage in gross negligence or willful misconduct. Life Sciences PA is pleased Senator Toomey agreed to co-sponsor this legislation.



## EXECUTIVE ORDERS ON DRUG PRICING

President Trump held a press event July 24 at the White House where he [signed four executive orders](#) aimed at lowering the cost of prescription medicines. The four executive orders focus on the following:

- **Requiring discounts through the 340B program at federally funded community health centers to be passed on directly to patients for insulin and EpiPens**
- **Making it easier for states, wholesalers and pharmacies to import medicines from Canada and other countries**
- **Passing some discounts received by Pharmacy Benefit Managers (PBMs) directly to patients by offsetting costs at the pharmacy counter**
- **Tying certain medicines covered by Medicare Part B to the lowest price paid in other developed countries in what the Administration is referring to as its “Most Favored Nation” (MFN) policy**

After signing the initial four executive orders, President Trump signed an [updated executive order](#) September 13. This order updates an existing executive order signed by the President in July that called for the U.S. Department of Health and Human Services to utilize a MFN pricing proposal that ties certain medicines covered by Medicare Part B to the lowest price paid in other developed countries. Unfortunately, the President’s new executive order expanded upon that initial order and now also includes certain medicines covered by Medicare Part D.

Healthcare almost always plays a central role in presidential election rhetoric and these executive orders, while not new ideas in Washington, reflect that. However, the executive orders utilizing MFN pricing are of significant concern to Life Sciences PA. They appear to focus on the most innovative medicines and will severely inhibit investment in future groundbreaking therapies and cures, all while pharmaceutical and biotechnology companies are on the front lines of developing vaccines and therapeutics for a global pandemic. Simply importing foreign price controls is an idea that will have negative consequences for both innovation and patient access to novel medicines.

Life Sciences PA will be monitoring these executive orders closely as more details emerge and implementation moves forward. Life Sciences PA will be working closely with national partners and allies in the Pennsylvania congressional delegation to ensure the Administration understands the life sciences community’s concerns and will submit comments to the U.S. Department of Health and Human Services/Centers for Medicare and Medicaid Services (CMS) as appropriate.



## EXECUTIVE ORDER ON THE DEFENSE PRODUCTION ACT (DPA)

The President [signed an executive order](#) August 6 utilizing the Defense Production Act (DPA) to procure essential medicines and medical supplies through domestic manufacturers and suppliers.

While the Administration has yet to release the list of “essential medicines” that will be included in this executive order, it appears to require federal agencies to give higher prioritization to medicines and medical equipment produced domestically. Life Sciences PA has concerns about how orders such as this could affect, especially in the short-term, the robust global supply chains upon which many of our Member companies rely. Life Sciences PA will continue to monitor the implementation of this order and make our concerns known to the Pennsylvania congressional delegation and administration.



## STATE



## STATE BUDGET CONTINUED


In late May, Governor Tom Wolf signed a five-month budget that funds state operations through November 2020. As such, the legislature, currently anticipating a \$3 billion to \$5 billion shortfall over 12 months, must pass a budget to fund the remaining seven months of the fiscal year in Pennsylvania ending June 30, 2021. Life Sciences PA continues to advocate for our priorities, including Association Health Plans, the Research and Development Tax Credit, the Keystone Innovation Zone Tax Credit and the Ben Franklin Technology Partners to be fully funded for the remaining seven-month budget.



## PA HOUSE DEMOCRATIC POLICY COMMITTEE HEARING ON COVID-19'S IMPACT ON INNOVATION

The Pennsylvania House Democratic Policy Committee convened an informational hearing September 21 on COVID-19's Impact on Innovation. Christopher Molineaux, President & CEO of Life Sciences PA testified at the hearing, along with Shawn Patrick O'Brien, Chief Executive Officer of Genomind and Jonathan Steckbeck, Founder and Chief Executive Officer of Peptilogics.

Their testimonies underscored the expensive, time-consuming and complicated path a life sciences company embarks upon to develop a new medicine. Further, each speaker explained how the global pandemic and related mitigation efforts interrupted that process and extended, or halted completely, their research and development timelines due to lab shutdowns, access to patients for clinical trials or fundraising interruptions because of the volatility of the markets.



Clockwise from top left: Jonathan Steckbeck, Representative Mark Longietti (D-7) (hearing room), Shawn Patrick O'Brien, Rep. Mary Jo Daley and Christopher Molineaux.



## *Content-driven initiatives* for biopharmaceutical companies



**Publication/Content  
Development**



**Innovative  
Technology**



**Meeting  
Planning**

**Want to learn more?** Contact us at: 610-321-1623 • [www.aoic.net](http://www.aoic.net) • [info@aoic.net](mailto:info@aoic.net)



# ELECTION PREVIEW

On November 3, the United States will elect its President for the next four years. This presidential race and the rhetoric surrounding it will dominate headlines and airwaves leading up to the election. However, there are many races on the ballot at the state and federal level that will determine who represents your interests in Harrisburg and Washington, D.C. Below is a short preview of the upcoming election (incumbents in **bold**).

## STATE:

### THREE STATEWIDE OFFICES ON THE BALLOT:

Attorney General: **Josh Shapiro (D)** v. Heather Heidelbaugh (R)

Treasurer: **Joe Torsella (D)** v. Stacy Garrity (R)

Auditor General (Open Seat): Nina Ahmad (D) v. Timothy DeFoor (R)

In the Pennsylvania State House, all 203 House seats are up for election. Republicans hold a majority of seats in the Pennsylvania House with 109 representatives, while Democrats hold 93 seats. There is currently one vacant seat – that of former Speaker of the House Mike Turzai who retired in June.

In the Pennsylvania State Senate, 25 of the 50 Senate seats are up for election. As it stands, Republicans hold a majority of seats in the Pennsylvania Senate with 28 seats, while the Democrats hold 21 seats (one seat is held by an Independent).

## FEDERAL:

At the federal level, neither Senator Toomey nor Senator Casey are up for reelection, as their six-year terms end in 2022 and 2024, respectively.

All 18 House seats are up for election. Currently the Pennsylvania delegation is evenly split between nine Democrats and nine Republicans. Below is a list of the races for all 18 U.S. House seats in Pennsylvania. The Cook Political Report cites the races in **blue** as “Races to Watch”, meaning they are close in polling and have been deemed highly competitive by other statistical analysis (incumbents in **bold**).

| DISTRICT | DEMOCRAT CANDIDATE      | REPUBLICAN CANDIDATE       |
|----------|-------------------------|----------------------------|
| 1st      | Christina Finello       | <b>Brian Fitzpatrick</b>   |
| 2nd      | <b>Brendan Boyle</b>    | David Torres               |
| 3rd      | <b>Dwight Evans</b>     | Michael Harvey             |
| 4th      | <b>Madeleine Dean</b>   | Kathy Barnette             |
| 5th      | <b>Mary Gay Scanlon</b> | Dasha Pruett               |
| 6th      | <b>Chrissy Houlahan</b> | John Emmons                |
| 7th      | <b>Susan Wild</b>       | Lisa Scheller              |
| 8th      | <b>Matt Cartwright</b>  | Jim Bognet                 |
| 9th      | Gary Wegman             | <b>Dan Meuser</b>          |
| 10th     | Eugene DePasquale       | <b>Scott Perry</b>         |
| 11th     | Sarah Hammond           | <b>Lloyd Smucker</b>       |
| 12th     | Lee Griffin             | <b>Fred Keller</b>         |
| 13th     | Todd Rowley             | <b>John Joyce</b>          |
| 14th     | William Marx            | <b>Guy Reschenthaler</b>   |
| 15th     | Robert Williams         | <b>Glenn ‘GT’ Thompson</b> |
| 16th     | Kristy Gribus           | <b>Mike Kelly</b>          |
| 17th     | <b>Conor Lamb</b>       | Sean Parnell               |
| 18th     | <b>Mike Doyle</b>       | Luke Negron                |




# PITTSBURGH BIOBREAKFAST'S FALL FLU VACCINATION CLINIC—A SHOT...AND A BEER!

The Pittsburgh BioBreakfast is a weekly gathering of individuals in the life sciences industry designed to bridge the groups that shape the region's biomedical sector. The weekly BioBreakfasts are led by Christian Manders, Chief Operating Officer of Promethean Lifescience, Inc. and are supported with funding from Life Sciences PA. Read below to learn how Christian kept an annual tradition alive, despite the pandemic, to benefit his local Pittsburgh community.

"Pittsburgh is a Shot and a Beer Town. The old standard dive bar order is an "Imp and Arn," to receive a shot of Imperial Whiskey (which you do not sip) and an Iron City beer. Pittsburgh is famous for Jonas Salk's Polio Vaccine and its penchant for over-imbibing cheap beer so we paired the two for a Shot and a Beer Vaccination Clinic. The Pittsburgh BioBreakfast hosts an Annual Flu Vaccination Clinic at one

of our Fall meetings. Since we are not meeting in person, we decided to take the Flu Clinic to the People. Working with our partner, Giant Eagle Pharmacy, we held a Flu Vaccination Clinic in the Bloomfield neighborhood, Pittsburgh's Little Italy, on Thursday, September 10. We vaccinated around 50 people, many older residents. Everyone of age also received a free beer for some socially distanced refreshment. Giant Eagle handled all of the billing and an anonymous donor covered any fees for uninsured individuals. Giant Eagle even added \$5 in free groceries to the Giant Eagle Advantage Card of everyone vaccinated. It was a great success and this is the year when everyone needs to get a flu vaccination."

**Christian Manders, Chief Operating Officer,  
Promethean Lifesciences, Inc.**



**ARE YOU IN THE PITTSBURGH AREA AND INTERESTED IN HOSTING  
A FLU VACCINATION CLINIC IN YOUR NEIGHBORHOOD?**  
CONTACT LAUREN M. POSTERARO, PHARMD, CLINICAL COORDINATOR, PITTSBURGH NORTH,  
GIANT EAGLE, INC. AT [LAUREN.POSTERARO@GIANTEAGLE.COM](mailto:LAUREN.POSTERARO@GIANTEAGLE.COM) TO GET STARTED!



# ABOUT Big4Bio

## THE ONE PLACE FOR EVERYTHING YOU NEED TO KNOW

The life sciences sector is witnessing unprecedented levels of innovation and investment, while the health care industry as a whole is in the midst of a sea change.

If you aren't a full-time analyst, how can you keep up and find the key information you need to make the right decisions for your business?

### THAT'S WHERE WE COME IN.

Big4Bio is the premier aggregator of financial, clinical and business news on the life sciences sector. Our free, daily emails give you easy-to-scan headlines on key developments and links to content gleaned from dozens of credible industry sources.

We produce individual summaries for the four most significant life sciences markets in the country:

**Boston, San Francisco, San Diego, and Philadelphia.**

You can choose to receive as many, or as few newsletters as you wish. You can find news on all of our regions as well as exclusive content on our website.

**Subscribe for FREE at [Big4Bio.com](http://Big4Bio.com)**

# Big4Bio

PHILADELPHIA

Greater Philadelphia's biomedical cluster is the natural out-growth of the region's proximity to the large pharmaceutical companies in southern New Jersey, the array of high-profile academic research and medical centers in Philadelphia and the region's legacy chemical companies.

The region is home to over 800 life sciences companies, 15 major health systems, four NCI-designated cancer treatment centers and seven medical schools. It is also site of the second-largest medical device clusters according to the industry association AdvaMed – ranking second behind California.

BigBio Communications is proud to showcase the news and developments from the Greater Philadelphia area.

PRESS RELEASES - FINANCIALS - MEDIA COVERAGE - EVENTS - SPOTLIGHTS

Subscribe FREE at [Big4Bio.com](http://Big4Bio.com)

# EVENTS

## LIFE SCIENCES PA'S DIVERSITY & INCLUSION INITIATIVE

In June 2020, Life Sciences PA issued a statement in response to America's renewed, intense focus on racial injustice and inequality. As we stated in that message, there are no simple answers or expedient solutions to address longstanding racism and systemic inequities afflicting our country. We also acknowledged, however, that it is not the nature of Pennsylvania's life sciences community to sit by idly while these problems persist. Our members work every day with passion, empathy and perseverance to find solutions to the most complex medical problems afflicting patients of all races, nationalities, and backgrounds.

The team at Life Sciences PA continuously strives to recruit a diverse programming agenda, and this year we are placing special emphasis on also increasing the diversity of our audience, in particular, increasing the diversity of our student audience. We firmly believe by focusing on our audience, we can make a larger impact resulting in increased diversity.

In an effort to promote access to Life Sciences PA's programming, we began our Diversity & Inclusion Initiative in July by offering complimentary student registrations to Life Sciences PA events. In order to share this offer with as many students as possible, we conducted outreach to the colleges and universities in our membership, to Historically Black Colleges and Universities, and to partner organizations to help spread the word.

Shortly after the inception of this Initiative, Life Sciences PA hosted its annual conference, Life Sciences Future - MedTech, from July 15-17, 2020. We were very pleased to see our initial round of outreach resulted in the registration of more than 150 students from 34 colleges and universities for Life Sciences Future - MedTech. We are proud of this number, but also understand there is plenty of room for growth and we will continue to offer scholarship opportunities for all our programs moving forward.

This Initiative would not be possible without the support from the Member companies who helped bring this Initiative to fruition. It is through our Members' generosity that we are able to cover the fees for student passes for underrepresented individuals who otherwise may not know about Life Sciences PA programs, or who may not have the financial resources to attend.

As we continue to see more and more diversity in our audiences, we are hopeful we can offer our community a space where everyone feels equally welcomed, valued and appreciated. But, our efforts have only just begun. We have plans to promote D&I within our existing programming, as well as through additional programming in the rest of 2020 and well into 2021. The life sciences community in Pennsylvania is strong and vast, and as we continue to prioritize this D&I Initiative, we invite you to continue sharing this offer with your network. We look forward to expanding our community of attendees and thank you in advance for supporting this effort.

Thank you to our generous sponsors of the Diversity & Inclusion Initiative:

**Teleflex®**

  
**AmerisourceBergen®**

 **Dova®**  
PHARMACEUTICALS

 **Idera**

 **intact®**  
vascular

 **MERCK**  
INVENTING FOR LIFE

**NEXEPTION**

**optinose®**

 **PassageBio**

**SANOFI** 

**troutman  
pepper**

**TUNNELL**   
life sciences consulting

## VIRTUAL LSPA COMMUNITY

Since the launch of the Virtual LSPA Community back in March, Life Sciences PA is pleased to announce that as of August 31, there are 412 participants in the Virtual LSPA Community representing 298 Member companies. Since its inception in early March, Members have continued to post on the virtual community wall, exchange digital business cards and send messages. This platform continues to facilitate connections during a time when in-person interaction is limited.

**Looking to join the Virtual LSPA Community?** It's not too late! Click [here](#) to join.

### SHARE YOUR UPDATES

Want to be featured here? Forward news articles, event recaps, or announcements to **Stephanie Webster** at [swebster@lifesciencespa.org](mailto:swebster@lifesciencespa.org) to be considered for our next issue.



@LIFESCIENCESPA



LIFE SCIENCES  
PENNSYLVANIA



FACEBOOK.COM/  
LIFESCIENCESPENNSYLVANIA



## LIFE SCIENCES FUTURE - MEDTECH

JULY 15-17, 2020 | HOSTED VIRTUALLY

Hundreds of viewers gathered virtually from July 15-17 for *Life Sciences Future - MedTech*, a three-day conference focused on timely topics and updates related to the medical device, diagnostic, and digital health communities, as well as all related stakeholders. Presenters showcased new scientific advancements while looking ahead at the future of the industry. *Life Sciences Future - MedTech* featured well-known speakers including:

- Dr. Jeffrey Shuren, Director of the Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration (FDA)
- Ian L. Valerio, M.D., M.S., M.B.A., FACS, Commander (CDR), Medical Corps, U.S. Navy, Plastic and Reconstructive Surgeon at Harvard Medical School and Massachusetts General Hospital
- Travis Mills, Retired US Army Staff Sergeant of the 82nd Airborne, Quadruple Amputee
- David B. Nash, MD, MBA, Founding Dean Emeritus at Jefferson College of Population Health, Thomas Jefferson University

Throughout the conference, attendees tuned in to virtual sessions, joined Zoom networking sessions and participated in one-on-one video partnering meetings. All conference speakers handled the transition from stage to webcam with ease and made Life Sciences PA's first-ever virtual conference and tremendous success.




Bruce Shook, President & CEO of Vesper Medical and LSF-MedTech's Conference Chair and Christopher Molineaux, President & CEO of Life Sciences PA welcomed registrants each morning of the conference.



# ANNUAL AWARDS PROGRAM VIP RECEPTION

JULY 27, 2020 | HOSTED VIRTUALLY

Ahead of the public premiere of the **2020 Annual Awards Program**, Life Sciences PA hosted a virtual **VIP Reception** that featured a preview of the documentary-style program. The group of honorees, members of the Life Sciences PA Board of Directors, the Life Sciences PA team, and colleagues from sponsoring organizations tuned in for the early reveal of the hour-long program. Life Sciences PA was pleased to host this Reception not only as a way for invitees to “see” each other virtually over Zoom, but also to provide a forum for further recognition for all the honorees and featured heroes of COVID-19.



# 2020 ANNUAL AWARDS PROGRAM

JULY 29, 2020 | VIRTUAL PREMIERE

Life Sciences PA's Annual Dinner, which typically sees over 1,400 members of the life sciences community join in person for a celebration of the industry's accomplishments, was modified this year to ensure the safety of our community.

Throughout March and April, the program for the renamed **2020 Annual Awards Program** evolved significantly and saw a COVID-19-prompted change to a virtual event. Despite the virtual hosting of the **2020 Annual Awards Program**, the Life Sciences PA team worked to ensure the program was much more impactful than the average Zoom call or webinar.

For the first time ever, Life Sciences PA's **2020 Annual Awards Program** premiered at 4:00 p.m. July 29, 2020. The documentary-style production focused on the successes of 2019, heroes of COVID-19, the current unrest in our country and, of course, the lifetime achievement of some of our community's leaders. In order to share the tremendous successes and accomplishments with the

largest audience possible, Life Sciences PA was pleased to share this production broadly on the Life Sciences PA website for anyone and everyone who was interested in viewing.

The virtual premiere of the documentary-style program did not require a ticket, however, tickets for the originally planned in-person event were nearly sold out. In an effort to contribute to our community, Life Sciences PA encouraged those who had already purchased a ticket for the 2020 Annual Dinner to donate the cost of their ticket to [Life Science Cares](#). Through the tremendous generosity of our community, Life Sciences PA was able to facilitate the donation of over \$165,000 to the Philadelphia chapter of Life Science Cares to support its work to reduce the impact of poverty on our neighbors in the greater Philadelphia area.

The **2020 Annual Awards Program** served as a way to safely unite our community, as it has for the past 30 years, at a time when a strong sense of community and camaraderie is most needed.



## Many Thanks to Our Event Sponsors



# BASICS OF BIOTECH

AUGUST 17-21, 2020 | HOSTED VIRTUALLY

*Basics of Biotech* was a comprehensive, virtual course comprised of half-day sessions from August 17-21 focused on the development of biopharmaceuticals. The course was curated for those who may be new to the biotechnology or pharmaceutical industry, those looking for a high-level understanding of drug development, or those wanting a refresher on the development process. *Basics of Biotech* was designed for anyone interested in learning more about the development process and required no prerequisite knowledge of the industry. Additionally, this course was of value to those who support any step within the development process of pharmaceuticals, including outside vendors.

The course began with foundational basics and gave a detailed overview of the entire process from discovery to commercialization. Attendees learned about the science behind biotech products, the clinical research process, regulatory filings, and scale-up for manufacturing. The program also explained the development process for products such as biologic




drugs and biosimilars, as well as the sciences behind personalized medicine, stem cell research, and regenerative medicine. New this year, attendees were able to earn up to 12 Continuing Learning Education credits upon completion of the course.

# BUILDING YOUR LSPA NETWORK

SEPTEMBER 1, 2020 | HOSTED VIRTUALLY

All new Life Sciences PA Members are encouraged to attend the *Building Your LSPA Network* event to jump start their immersion into the Life Sciences PA community. In the beginning of September, members from across the state of Pennsylvania joined this virtual event to learn about their Life Sciences PA membership, meet some of their peers, and begin networking. Christopher Molineaux, President & CEO of Life Sciences PA, opened the event with an overview of Life Sciences PA and its mission. He also explained how any discipline that touches the life sciences industry is represented within Life Sciences PA's membership. Leading the event and facilitating the discussion were Tom Hess, Senior Vice President and CFO of Genomind, and Charlie Huntington, Managing Director-Investment Officer at Huntington Kraus Financial Group of Wells Fargo Advisors. Tom and Charlie explained how the Life Sciences PA network has helped them grow personally and professionally, and how getting involved in the Life Sciences PA community is the key to a successful membership.



Represented new Member companies included:

Canopy Biopharma | Chimeron Bio  
Contemporary Publishing Group East | Lean for Humans  
NEXClean | Medix | Social Assurance Media  
Solomon Page | Volpe Koenig

# WE ADVANCE THE HEALTH OF CHILDREN BY TURNING SCIENTIFIC DISCOVERY INTO MEDICAL INNOVATION

Children's Hospital of Philadelphia Research Institute is one of the largest pediatric research programs in the world. Our research and expertise have led to advancements in preventative care as well as treatments for nearly a century.

To learn more, please visit our website at <https://www.research.chop.edu> and subscribe to our blog at <https://blog.research.chop.edu>



# CONTINUING BUSINESS THROUGH COVID-19: in their own words

Since mid-March, many organizations have adapted plans and processes to continue their efforts in a safe, sustainable way. But how exactly did they do it? How have organizations managed to continue their operations despite such drastic changes to the working environment? This is a sampling of how Member organizations have managed to continue business as usual, or rather, as close to usual as possible, during the pandemic. CEOs across our membership answered these four questions ▼

- 1 While the global pandemic was certainly not predicted, do you feel your organization had adequate business continuity plans in place and was prepared for this dramatic interruption of operations?
- 2 What aspect of COVID-19 has been the biggest barrier to conducting business as usual, and how have you overcome that barrier?
- 3 What is one thing you learned in the last six months that will be most beneficial to company operations going forward?
- 4 How has your team managed short-term issues and challenges related to COVID-19 while maintaining focus on your organization's long term mission, goals and company culture?

Read how several of our member organizations, in their own words\*, are faring in the midst of COVID-19.

## IN THE WORDS OF...



**Michael J. Annichine**  
Chief Executive Officer,  
Magee-Womens Research  
Institute & Foundation



**Christopher J. Burns, Ph.D.**  
Founder, President and  
Chief Executive Officer,  
Venatorx Pharmaceuticals



**Felix Hsu**  
Chief Commercial and  
Business Officer,  
WuXi Advanced Therapies



**Steven Kelly**  
President & CEO,  
Carisma Therapeutics



**Jeff Tyber**  
President, CEO, and Founder,  
Tyber Medical LLC



- 1 While the global pandemic was certainly not predicted, do you feel your organization had adequate business continuity plans in place and was prepared for this dramatic interruption of operations?

“Tyber Medical was able to navigate this dramatic interruption by using its ability to pivot as a company. We created a new remote workforce, changed communication channels (i.e. Zoom, Webx) through a true team effort.

This was done in a rapid response to the pandemic, and we credit our tremendous employees for making this happen!”

– Jeff Tyber

“As Venatorx Pharmaceuticals has grown over the years, we steadily built our IT infrastructure to support frequent “remote” interactions. This was, partly, precipitated by the fact that several of our team members live in other regions of the country. As COVID-19 hit, we were fortunate to be well equipped to support our entire team needing to work in a virtual environment, leveraging tools like Microsoft Teams, Zoom, etc. During the RED and YELLOW Phases, we held weekly virtual town hall meetings to address concerns, answer questions, alleviate fears and reassure our team that we are in this together to support them and their families. As new information surfaced—minute-by-minute, hour-by-hour—we adapted and changed course wherever possible.”

– Christopher Burns

“It’s hard to plan for every eventuality, when COVID hit we had continuity plans in place for some aspects of our business but not all. Once the impact of the virus became apparent we moved quickly to develop a plan for how we would continue to operate aspects of the business virtually which minimized the disruption. We implemented new protocols to protect lab based staff, enabled office staff to work from home using Zoom meetings, and worked closely with our facility management company and CDMO’s to ensure successful functioning of labs and manufacturing operations.” – Steven Kelly

CONTINUED ON NEXT PAGE

\*LSPA staff edited for length.

## 1 While the global pandemic was certainly not predicted, do you feel your organization had adequate business continuity plans in place and was prepared for this dramatic interruption of operations? (continued)

*"Many MWRI employees were able to seamlessly transition to home offices during the beginning of this pandemic. Our Administrative and Foundation offices were able to adapt and fully continue operations, although we needed to shift the way in which we did business. For example, fundraising has traditionally been a face-to-face business. Because of the pandemic, we needed to change how we were reaching out to donors and building brand awareness. Virtual events, social media challenges, wellness calls and zoom meetings quickly took over traditional fundraising efforts.*

*Outside of essential employees that continued work in their research units throughout the pandemic, many of our researchers switched gears to grant-writing, publishing papers (MWRI has more than 2500 scientific publications), professional development and even helping out in other research units until they could comfortably work back in their individual labs.*

*Instructions on COVID-19 safety precautions and regulations came from both Pitt and UPMC, however MWRI quickly created a COVID-19 rapid response team where we continue to communicate company-wide on safety precautions, COVID-19 progression in Allegheny County and beyond, and created new policies to be able to continue our work." – Michael J. Annichine*

## 2 What aspect of COVID-19 has been the biggest barrier to conducting business as usual, and how have you overcome that barrier?

*"Fear has been the biggest challenge. We have implemented safety recommendations given by the CDC and federal government, but in addition have proactively been ahead of the safety curve all along. (For example we had digital thermometers at all entrances, gloves and masks before it was required.)" – Jeff Tyber*

*"Inability to visit customers or have them visit our site. Use of Zoom and remote tours. Need for spacing and keep people safe. Only essential people on site, more remote work, better safety measures." – Felix Hsu*

*"Global shutdowns have caused a direct effect on both our internal lab operations as well as contracted vendor and clinical trial operations. This delayed—or halted—several initiatives. We have been working very hard to get all of these projects back up and running, with increased success during the last 3 months." – Christopher Burns*

*"After a short period of time at the start of the pandemic, when we were taking stock and trying to assess the situation, we have been able to continue the vast majority of our business operations with minimal disruption. We have seen some impact on site initiation for our Phase 1 clinical study due to delays from contracting groups/ IRB's being able to operate as normal, however, these are now back up and running and we're on track to start our trial in Q4. Additionally, to protect against any future delays to patient recruitment we decided to initiate a second site." – Steven Kelly*

## 3 What is one thing you learned in the last six months that will be most beneficial to company operations going forward?

*"How to keep the work force as protected as possible: spacing, wiping down, temperature monitors, contact tracing, etc. and how people are working remotely more effectively." – Felix Hsu*

*"We firmly believe this pandemic has put an emphasis on the need to focus on the science (Covid-19 and traditional research) and we intend to use the work we have done over the last 2 years to speak to that.*

*We are challenging ourselves in every way to emerge more insulated from any and all future unknowns by redefining how we do business today both from a fundraising and an operation perspective.*

*We also learned that being able to operate your business remotely and have a team that can adapt quickly from the way we used to do things to the new ways of thinking is key. I'm fortunate to have an executive team that is self-driven and passionate about pushing the needle, even during a pandemic." – Michael J. Annichine*

*"The importance of maintaining a sense of community within the organization without having the opportunity to interact in person." – Steven Kelly*

\*LSPA staff edited for length.

#### 4 How has your team managed short-term issues and challenges related to COVID-19 while maintaining focus on your organization's long term mission, goals and company culture?

*"Clear communication of the company's strategic objectives for the year to ensure everyone is aligned on what we need to do to be successful. Regular townhalls to update staff on the latest plans for managing COVID, and how the organization is progressing towards its goals. Finding ways to inject some fun and drive interaction beyond the business updates, including virtual quiz nights, happy hours etc."*  
**- Steven Kelly**

*"The more you talk about COVID-19, the more you will talk about COVID-19. Common sense has needed to intervene where media and political hysteria has not. Practicing social distancing, wearing masks, and washing hands are clearly an effective way for employees to protect themselves, even if they are unsure of the status of others. We have slowly been able to bring the team back onsite, practicing these simple protections and using common sense. Combining online meetings and onsite interactions has boosted morale and allowed a more optimal business setting."* **- Christopher Burns**

*"By a true team effort and caring about one another. Each employee has a story outside of work. Tyber Medical as a team, strives to help each employee with issues both on and off the clock so they can remain focused on our mission, culture, and goals."* **- Jeff Tyber**

*"Manage the day to day, while also working on our 3 year plan. Work to connect the two as much as possible."* **- Felix Hsu**

*"Our internal values at MWRI are Impact, Convergence, Mentoring and Openness. In my meetings, I always start with a slide showing these values to make sure our thought process for decisions made were geared toward enforcing them. Our number value is to create positive impact in communities all around the world and staying focused on that led the way. Focusing on our goal being impact while realizing that research was simply one of our tools allowed us to not only prioritize our research based on current needs, but also think about communication, education and other activity that can help create that impact."*

*While there have certainly been some challenges these past seven months, what we do at MWRI is rewarding work and our staff has never lost sight of the fact that we are 'changing the way the world treats women'. This pandemic just expanded our opportunity to do so. We pointed our infectious disease resources towards COVID-19 and are working on a preventative therapeutic."*

*Our culture, vision and values have been strengthened by our actions during this time."* **- Michael J. Annichine**

\*LSPA staff edited for length.

Financial healthcare for your future.  
[investwithhk.com](https://investwithhk.com)

#### Investment and Insurance Products:

- Not FDIC-Insured
- No Bank Guarantee
- May Lose Value

**HUNTINGTON♦KRAUS**  
 FINANCIAL GROUP  
*of Wells Fargo Advisors*

**Wells Fargo Advisors is a trade name used by Wells Fargo Clearing Services, LLC, Member SIPC, a registered broker-dealer and non-bank affiliate of Wells Fargo & Company.**



## 2020 NEW MEMBERS YEAR-TO-DATE

As of 9/14/2020

ADARE PHARMACEUTICALS

ADVANCED CLINICAL

AMBULATUS ROBOTICS

APPIAN CORPORATION

BANCROFT CONSTRUCTION  
COMPANY

BI WORLDWIDE

BLACKFYNN, INC.

BLUE SPARK TECHNOLOGIES

BRENTWOOD INDUSTRIES, INC.

CONTEMPORARY PUBLISHING  
GROUP EAST

CORPORATE-INTERIORS

DISCOVERY SEARCH PARTNERS

DRUGSMITH CONSULTING

EXTEND DEVICE CORPORATION

FIRSTLIGHT PHARMACEUTICALS

HEALTHQUEST CAPITAL

KYOWA KIRIN

LABCONNECT

LAVA THERAPEUTICS B.V.

LIFESCAN, INC.

LIVANOVA- TANDEMLIFE, CO.

LUCASPYE BIO, LLC

MEDIX

MERZ

NEURAPTIVE THERAPEUTICS, INC.

NEXCLEAN

PINNAQL INC.

POCONO RABBIT FARM & LAB  
INC.

PREMIER FOCUS SOLUTIONS

PROXUS HR

SAVIO GROUP ANALYTICS/ SAVIO  
GROUP INC.

SENECA THERAPEUTICS, INC.

SOCIAL ASSURANCE MEDIA

SOLOMON PAGE

TAIHO ONCOLOGY, INC.

TOTAL PACKAGE PARTNERS

TRADECRAFT CLINICAL RESEARCH,  
LLC

VIVASC THERAPEUTICS, INC.

VOLPE AND KOENIG

ZYVERSA THERAPEUTICS

## 2020 DIAMOND MEMBERS



# UPCOMING EVENTS IN Q4 2020

## Education Event | November 2020

This **Education Event** will focus on Supply Chain and “Contracting with Partners in The New World”. The event’s Featured Speaker is Deborah Spranger, Partner, Troutman Pepper. Additional details to come.

## Tell Me About Your Job Series | Fall 2020

**Tell Me About Your Job** will be a live 30-minute bi-weekly online program that will kick off this fall. This program will feature underrepresented scientists, executives and leaders from the life sciences industry who will answer a series of questions that Life Sciences PA will collect through a survey of the targeted student population. The selected speakers and questions will be designed to show students there are individuals in our industry who look just like they do and have come from similarly challenged backgrounds where racism and socioeconomic hardship were realities. Through this initiative, we hope to provide all students the ability to picture themselves in various roles within the life sciences industry by highlighting the diversity that exists in our community.

## Basics of Biotech | November 17-20, 2020

**Basics of Biotech** is a comprehensive, virtual course comprised of four half-day sessions designed to provide you with an overview of the development of biopharmaceuticals. The course will start with foundational basics and give a detailed overview of the entire process from discovery to commercialization.

## Clinical Trial Summit | November 20, 2020

The 2020 **Clinical Trial Summit** is a half-day program created specifically for those planning and conducting clinical trials, or those who are seeking advice when selecting outsourced providers. The Summit is designed for:

- Individuals interested in becoming involved in a strategic partnership with a CRO or CMO in the next 12-18 months
- Biotechnology, pharmaceutical, medical device or diagnostic companies planning a clinical trial
- Individuals who have secured a CRO and CMO, and the relationship has not been successful

## Scrub Your Deck | November 2020

**Scrub Your Deck** is a special program designed to enhance Members’ experiences during investment pitches. The event is created to showcase the best and brightest emerging companies while also providing them the critical coaching, counseling, and feedback they will need to make successful funding pitches and advance their companies in 2020 and beyond. Additional details to come.

## CEO Dinner | Winter 2020

This virtual event is reserved for Chief Executive Officers of Life Sciences PA member organizations involved in biotechnology or pharmaceutical research and development, drug discovery, medical device development, and contract research organizations involved in preclinical research. Additional details to come.

## THE LIFE SCIENCES PENNSYLVANIA TEAM

CHRISTOPHER P. MOLINEAUX  
President & CEO  
cmolineaux@lifesciencespa.org  
610-947-6800 ext. 203

KAREN DELONE  
Senior Vice President &  
Chief Operating Officer  
kdelone@lifesciencespa.org  
610-947-6800 ext. 210

### ADVOCACY

KURT IMHOF  
Vice President, Policy and Public Affairs  
kimhof@lifesciencespa.org  
610-947-6800 ext. 211

JENNIFER YOUNG  
Senior Director, Policy & Public Affairs  
jyoung@lifesciencespa.org  
412-584-7651

### OPERATIONS

BETTY PIKE  
Accountant  
bpike@lifesciencespa.org  
610-947-6800 ext. 207

JAMIE BUBECK  
Accountant Level 2  
jbubeck@lifesciencespa.org  
610-947-6800 ext. 218

### PROGRAMS

MELISSA CALLUM  
Director, Programs  
mcallum@lifesciencespa.org  
610-947-6800 ext. 208

JILL HUBER  
Director, Programs  
jhuber@lifesciencespa.org  
412-584-7651

LAUREN BOYLE  
Programs Coordinator  
lboyle@lifesciencespa.org  
610-947-6800 ext. 206

### MEMBERSHIP

PAUL KORNB�ITH  
Director, Western Pennsylvania  
pkornblith@lifesciencespa.org  
724-444-6128

LOIS STEPHENS  
Membership Manager  
lstephens@lifesciencespa.org  
610-947-6800 ext. 209

NICOLE MEROLLA  
Membership & Programs Coordinator  
nmerolla@lifesciencespa.org  
610-947-6800 ext. 204

### COMMUNICATIONS

STEPHANIE WEBSTER  
Manager, Communications  
swebster@lifesciencespa.org  
610-947-6800 ext. 217